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Drugs have been implicated in lung injury as a result of direct pharmacological action, persistence or metabolism in the tissue, or via
the production of a reactive metabolite or metabolites. The result of this apparent drug-associated injury ranges from cellular
dysfunction through to cell death (apoptosis) and alteration of repair mechanisms that are essential in replacing critical tissue elements
and function. There is limited knowledge on how timing of drug administration or drug interactions may interfere with the repair
mechanisms or modulate the expression of pulmonary toxicity. Chemotherapeutic drugs and novel agents, such as those targeting
the epidermal growth factor receptor (EGFR), appear to affect both normal and neoplastic cells. However, unlike chemotherapy,
where the actions are systemic and directly as a result of biotransformation or cell injury, it has been postulated that effects of EGFR-
targeting agents are more likely to be focused on epithelia via a pharmacological effect. Furthermore, risk factors for the development
of adverse pulmonary reactions, as well as biological markers indicating incipient toxicity, need to be prospectively identified.
Proteomics, through the identification of X1000 proteins or peptides in blood samples, will hopefully identify candidates for this role.
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INJURY AND REPAIR IN THE LUNGS
Pulmonary drug toxicity is increasingly being recognised as a
cause of interstitial lung disease (ILD) and, as this lung disorder
can be progressive and fatal, early recognition is important.
However, drug-associated ILD can be difficult to diagnose, as we
have seen in earlier sections of this supplement (see Camus et al,
2004 and Mu ¨ller et al, 2004). There is a limited understanding of
the mechanisms of drug-associated injury of the lung, compared
with other tissues such as the liver, and no specific markers exist
to differentiate drug-associated ILD from other pathological
processes. Also, many drugs are used simultaneously or in
close sequence and that makes assignment of toxicity to a specific
agent difficult. In particular, ILD may be a comorbid condition
of lung cancer, seen at the onset of disease and after many forms
of chemotherapy. Numerous questions remain unanswered with
this condition: in what manner do drugs or chemicals cause cell
injury in the lung; why do they cause injury in the lung and not in
other organs; why do they cause injury in only a minority of
patients?
Alveolar and bronchial epithelial cells may be injured by
inhalation of a drug or through the vascular system (Campbell and
Senior, 1981; Kay, 1986; Shimabukuro et al, 2003). Acute injury
seems to progress to chronic inflammation aided by T-lympho-
cytes and macrophages. Continued exposure to an antigen or
failure of the lung’s intrinsic anti-inflammatory mechanisms have
been suspected as causes of persisting inflammation. Whatever the
cause, this inflammation may in some instances lead to a fibrotic
change that ultimately interferes with gas exchange. In some forms
of ILD, the alveoli fill with lipoproteins, blood or eosinophils, in
others there is an unexplained proliferation of smooth muscle
mass, while still others result in amyloid deposits in the alveolus
and the alveolar capillary membrane. Less extensive pathological
changes are potentially reversible. The primary goal of treatment is
to suppress the inflammatory response and reverse the deposition
of granulation tissue.
In response to injury to the bronchial epithelium, there is an
immediate requirement to initiate tissue repair and restore barrier
function (Matthay, 1994). This involves migration of epithelial cells
adjacent to the area of damage into the wound to form a temporary
barrier consisting of poorly differentiated cells. However, as these
cells are unlikely to perform the normal differentiated functions of
epithelium, there follows a period of cell division and rediffer-
entiation, leading to a complete restoration of normal epithelial
barrier function.
Epithelial apoptosis
Apoptosis, a feature of normal and injured alveolar epithelium,
is a natural series of events in a cell that leads to its death. A
substantial body of literature supports a role for apoptosis in the
remodelling of lung tissue after acute lung injury for both the
clearance of excess epithelium cells after repair (Bardales et al,
1996) and the normal removal of excess mesenchymal cells from
resolving lesions (Polunovsky et al, 1993).
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interact with soluble proteins or membrane-bound proteins such
as Fas ligand (FasL). Fas ligand is a cell surface molecule expressed
predominantly in activated T-lymphocytes and natural killer cells
(Suda et al, 1993) and is involved in the downregulation of
immune reactions (Brunner et al, 1995; Ju et al, 1995). The
activation of death receptors, such as Fas, result in the recruitment
of adaptor proteins through interaction of a death domain
(Figure 1) (Kuwano et al, in press). Recruitment of Fas-associated
death domain to Fas activates caspase-8.
Stimuli other than death receptor activation (e.g. anticancer
drugs, radiation and reactive oxygen radicals) that can trigger
apoptotic pathways initiate at the mitochondria. Cytochrome c is
released into the cytosol from the mitochondria and binds to
Apaf1 with adenosine triphosphate, resulting in the activation of
caspase-9. The activation of caspase-8 or -9 leads to the activation
of the caspase cascade. Fas ligand accumulates in soluble form at
sites of tissue inflammation and has the potential to initiate
apoptosis of leucocytes, epithelial cells and other parenchymal
cells. It is possible that Fas, FasL, p53, p21 and other apoptosis-
regulating proteins play an important role in the pathophysiology
of lung injury and fibrosis. Animal studies have suggested that the
Fas–FasL pathway plays an essential role in the development of
pulmonary fibrosis and that inhibiting this pathway could have
therapeutic value in lung injury and apoptosis (Hagimoto et al,
1997; Kuwano et al, 1999a). DNA damage or apoptosis has also
been demonstrated in bronchial and alveolar epithelial cells in
patients with idiopathic pulmonary fibrosis (Kuwano et al, 1996).
Although the mechanisms by which lung fibrosis develops are
not fully understood, recent findings suggest that oxidative stress
may play an important role in the pathogenesis of tissue fibrosis
affecting apoptosis of both structural and inflammatory cells and
altering the cytokine microenvironment balance. Indeed, a study
that investigated oxidative stress and mitochondrial damage in
lung epithelial cells from idiopathic interstitial pneumonias
suggested that oxidative stress may participate in epithelial cell
damage in idiopathic interstitial pneumonia (Kuwano et al, 2003).
Increased production of transforming growth factor beta
(TGF-b) was demonstrated in epithelial cells of terminal airways
and alveoli in idiopathic pulmonary fibrosis (Khalil et al, 1991).
In addition to multiple effects on the process of fibrogenesis,
TGF-b1 can induce apoptosis in various cells. The mechanism of
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Figure 1 Apoptosis signalling pathways mediated by Fas or mitochondria (Kuwano et al, in press). Reprinted with permission from: Kuwano et al (in
press). Epithelial cell apoptosis in lung injury and fibrosis (see Kuwano et al, in press). FasL¼Fas ligand; FADD¼Fas-associated death domain;
MORT1¼Mediator of receptor-induced toxicity 1; CAD¼caspase-activated deoxyribonuclease; 1CAD¼inhibitor of CAD; Apat-1¼apoptotic protease
activating factor-1.
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TGF-b1 is a potent inducer of apoptosis through caspase-3
activation and the downregulation of p21. It is also an enhancer
of Fas-mediated apoptosis of lung epithelial cells (Hagimoto et al,
2002). p21 regulates the activation of caspase-3 through the
procaspase-3–p21 complex formation and protects human hepa-
toma cells from Fas-mediated apoptosis (Suzuki et al, 1998, 1999).
TGF-b, p53, p21 and Fas are predominantly localised in the
epithelial cells of the terminal airways and alveoli. It has been
speculated that these proteins and the Fas–FasL pathway, which
may be linked to each other, regulate the proliferation and death of
bronchial and alveolar epithelial cells (Kuwano et al, 1999b).
Loss of stem cells from epithelial surfaces
Acute lung injury is usually characterised by significant damage to
the alveolar epithelial barrier and efficient regeneration of an intact
epithelium is crucial to restore normal function of this barrier. The
type II pneumocyte is the stem cell of alveolar epithelium and is
primarily responsible for re-epithelialisation and restoration of
normal alveolar architecture. During normal cell turnover or lung
damage, these cells divide and differentiate into the predominant
alveolar type I pneumocyte (Uhal, 1997; Fehrenbach, 2001).
Widespread loss of the integrity of the non-neoplastic type I and
II pneumocytes appears to be the primary cause of diffuse alveolar
damage, which is characteristic of acute interstitial pneumonia.
Differential expression of the epidermal growth factor
receptor (EGFR) in normal and injured tissues
Members of the epidermal growth factor (EGF) family (i.e. EGF,
transforming growth factor alpha [TGF-a], heparin-binding EGF-
like growth factor [HB-EGF], amphiregulin, betacellulin and
epiregulin) are likely to be important regulators of epithelial
repair by virtue of their ability to stimulate cell migration,
proliferation, differentiation and survival. Indeed, EGF, HB-EGF
and TGF-a are known to have a direct role in cutaneous wound
healing (Lawrence and Diegelmann, 1994; McCarthy et al, 1996).
EGF belongs to a family of growth factors that exert their
biological effects by binding to and activating the EGFR (c-erbB1).
The EGF and EGFR play a pivotal role in maintenance and repair
of epithelial tissues; however, little is known about c-erbB
receptors and their ligands in human bronchial epithelium. Much
of the work on the EGFR in the lung has been performed in the
context of cancer, where elevated EGFR expression is a frequent
observation. This has led to EGFR-targeted agents, such as the
EGFR tyrosine kinase inhibitor (EGFR-TKI) gefitinib (‘Iressa’),
being developed for the treatment of non-small-cell lung cancer
(NSCLC). In normal adult lung, the distribution of EGF and EGFR
has been demonstrated by immunohistochemistry, with expression
observed in the basal cell layer of the bronchial epithelium (Aida
et al, 1994; Yoneda, 1994; Polosa et al, 1999) and in occasional type
II alveolar pneumocytes (Aida et al, 1994). As EGF signalling may
represent an important mechanism that helps coordinate the
process of recovery from lung injury (Polosa et al, 1999;
Puddicombe et al, 2000), it is possible that EGFR inhibition will
partly reduce the ability of pneumocytes to respond to lung injury.
Indeed, there have been reports of pulmonary toxicity with the
EGFR-TKIs gefitinib (Forsythe and Faulkner, 2003; Inoue et al,
2003) and erlotinib (Dragovich et al, 2003; Tan et al, 2003;
Yamamoto et al, 2003), as discussed elsewhere in this supplement
(see Camus et al, 2004).
MECHANISMS OF DRUG-ASSOCIATED CELL INJURY
The pathogenesis of drug-associated cell injury usually involves
the participation of toxic drug metabolites that either elicit an
immune response or directly affect the biochemistry of the cell
(Kaplowitz, 2002). Some molecules can also elicit an effect directly
rather than through metabolites, although such direct effects
appear much less common. Drug metabolites derived by
biotransformation can be associated with a variety of biochemical
events, such as oxidative stress, redox changes, covalent binding
and lipid peroxidation, which are linked with cell dysfunction and
ultimately cell death. Furthermore, many potent mutagens may
react with DNA to form covalent adducts, which are associated
with mutations in proto-oncogenes or tumour suppressor genes
and initiate cancer.
Biotransformation
The most common transformation of drugs is by oxidation, which
can produce reactive oxygen species capable of causing cell injury.
There are several defence systems against reactive oxygen species
and these include enzymatic systems, which contain enzymes that
can inactivate the active oxygen species, or nonenzymatic systems,
which will scavenge these oxygen radicals.
If the defence systems against toxic oxygen species are
overwhelmed, a condition known as oxidative stress arises. One
outcome of oxidative stress is lipid peroxidation that may lead to
cell dysfunction/death. Furthermore, inflammation and impaired
repair may also occur. The classic example of drug-associated
oxidative stress in the lung is paraquat. Paraquat, a quaternary
nitrogen herbicide, is a highly toxic compound that causes
intracellular oxidative stress with the production of reactive
oxygen species (Lewis and Nemery, 1995). In addition, nicotina-
mide adenine dinucleotide phosphate is depleted and the
antioxidant defence system is overwhelmed (Keeling and Smith,
1982).
The same or a similar mechanism is probably involved with
nitrofurantoin and possibly bleomycin. This explains why
hyperoxia may increase the damage because hyperoxia will
increase the production of reactive oxygen species and also further
deplete the defence systems. The presence of transition metals
augments these reactions with reactive oxygen species as they are
considered dependent on free iron.
Cytochrome P450 (CYP) and glutathione S-transferase
enzyme systems of the lungs
Cytochrome P450s comprise a superfamily of enzymes crucial for
the oxidative, peroxidative and reductive metabolism of a diverse
group of compounds, such as endobiotics, bile acids, fatty acids,
prostaglandins, leukotrienes and xenobiotics, including most
therapeutic drugs and environmental pollutants (Nelson et al,
1996; Bertz and Granneman, 1997). These enzymes are predomi-
nantly present in the liver but lower levels have been detected in
the lung (Nemery et al, 2001). Humans have been estimated to
have at least 53 different CYP genes and the CYP1A1 (in smokers),
2B6, 2E1, 2J2 and 3A5 proteins are expressed in human lung.
The cell-specific localisation of individual CYP enzymes in the
lung is poorly understood. However, according to immunohisto-
chemical analyses, expression is widespread, occurring in various
structures in bronchial and bronchiolar epithelium, Clara cells,
alveolar lining cells and alveolar macrophages (Hall et al, 1989).
CYP1A1 is mainly expressed in the epithelium of the peripheral
airways (bronchiolar, terminal bronchiolar and alveolar epithe-
lium) and is only observed in the lungs of smokers (Anttila et al,
1991). The most important other CYP enzyme identified in the
lungs is CYP3A, localised to bronchial, bronchiolar and alveolar
epithelium as well as alveolar macrophages.
Acetaminophen (paracetamol) is a common drug and can be
conjugated in the liver to sulphate or glucuronic acid. If
concentrations are too high and the conjugations are overwhelmed
(e.g. by an overdose) oxidation occurs by CYP or possibly by
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covalently bind to proteins, leading to oxidative stress, or engage
in toxic oxygen species production. Common drugs such as
acetaminophen can also be metabolised in the lungs and probably
cause damage or be associated with decreased antioxidant defence
(Dimova et al, 2000).
Differential metabolism in the lung
Some drugs are biotransformed differently in the lung from the
liver. Indeed, there is a range of experimental pneumotoxic agents
that have been shown to undergo specific metabolism in the lungs
and hence cause injury selectively in the lung. For example,
administration of naphthalene to male Swiss mice resulted in
severe bronchiolar epithelial necrosis at doses at which hepatic and
renal necrosis were not observed (Warren et al, 1982). Butylated
hydroxytoluene (BHT) also causes pulmonary toxicity. Lungs from
female mice injected intraperitoneally with BHT were injured
(Marino and Mitchell, 1972).
A toxic metabolite may be produced when the lung is
responsible for metabolism compared to the liver or, alternatively,
if there is failure of detoxification of the active metabolite in the
lung compared to the liver; these differences are often highly
species-specific.
Individual susceptibility
Drug toxicity may simply be a question of dose, and a high dose
will cause a pharmacological-type reaction. Thus, drug toxicity
may arise from ‘therapeutic misadventures’, such as drug–drug,
drug–diet or drug–environment interactions. Alternatively, drug
toxicity may be unpredictable or idiosyncratic.
For instance, alterations in biotransformation can be acquired as
a result of therapeutic misadventures. Antioxidants may become
depleted, hence reducing the cell’s ability to survive oxidative
stress. Genetic deficiencies in drug metabolism enzymes may also
lead to susceptibility to certain drugs that require detoxification.
One example is the common genetic polymorphism in the drug
metabolism enzyme N-acetyltransferase, which is responsible for
metabolism of the antituberculosis therapy izoniazid. An anecdotal
example of a genetic deficiency associated with lung toxicity was
published as a case report (Ackerman et al, 1988). A child with
partial monosomy 21, which leads to halving of superoxide
dismutase levels in the blood and lungs, was exposed to nontoxic
oxygen levels during an operation. The child suffered severe
pulmonary oedema, possibly due to an increased lack of defence
against toxic oxygen species.
HOW MIGHT RADIATION, CHEMOTHERAPY AND
EGFR INHIBITION BE ASSOCIATED WITH LUNG
INJURY?
Standard treatments for lung cancer have been associated with
ILD. Radiation can cause acute or chronic injury depending on
dose, duration, pre-existing lung disease and concomitant steroid
use (Abid et al, 2001; Aviram et al, 2001). There have also been
reports of ILD thought to be associated with lung cancer
chemotherapy, such as gemcitabine (Lilly, 2003), docetaxel
(Kunitoh et al, 1996; Merad et al, 1997; Wang et al, 2001),
paclitaxel (Furuse et al, 1997), irinotecan (Fukuoka et al, 1992) and
vinorelbine (Furuse et al, 1994). Treatment of NSCLC with
combination chemoradiotherapy has been associated with the
development of ILD (Schweitzer et al, 1995; Reckzeh et al, 1996;
Yamada et al, 1998; Robert et al, 1999; Aviram et al, 2001; Komaki
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Figure 2 Development and diagnosis of ILD.
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may be associated with pulmonary toxicity.
The development of ILD (Figure 2) associated with anticancer
agents is considered to be a multistep process, although one of the
key initiating factors is likely to be the apoptosis of non-neoplastic
type I and II pneumocytes. Mitochondrial-mediated apoptotic
pathways, activated in lung tissues from patients with idiopathic
interstitial pneumonia, may be involved in the pathophysiology of
the disease (Kuwano et al, 2002). Radiotherapy and chemotherapy
are unselective, damage DNA or alter repair, and will be likely to
precondition the lung alveolar epithelium; however, as only a small
fraction of patients develop ILD, it is likely that a further trigger
factor, such as infection, is needed in preconditioned alveolar
epithelium to cause ILD through impaired repair. While EGF
signalling probably represents another potential mechanism that
helps coordinate the process of recovery from lung injury by
stimulating epithelial repopulation and restoration of barrier
integrity (Aida et al, 1994), it is possible that EGFR inhibition,
such as with gefitinib, will at least partly impair the ability of
pneumocytes to respond to lung injury. Furthermore, it is very
clear that any potential association of ILD with gefitinib is likely to
be a pharmacological effect through EGFR on this repair process
and not a result of biotransformation or chemical injury, as with
radiotherapy and chemotherapy. However, to further understand
the mechanisms involved in EGFR inhibition and ILD it would be
interesting, through further research, to elucidate the key cell types
involved (e.g. type II pneumocytes).
PROTEOMICS AS A MEANS OF IDENTIFYING THE
MECHANISM OF ILD AND POTENTIAL DIAGNOSTIC
MARKERS FOR THE DISEASE
Background of proteomics
The high incidence, severity and unpredictability of ‘chemotherapy
lung’ has led many investigators to examine whether early
detection of the disease is possible, using pulmonary function
tests or imaging techniques (Wall et al, 1979; Castro et al, 1996;
Cottin et al, 1996; Dawson et al, 2002). Some investigators believe
it is prudent to discontinue chemotherapy once the diffusing
capacity for carbon monoxide has dropped to p50% of the
pretherapy value (Castro et al, 1996). In contrast, others do not
rely on this measurement since they believe that a decrease in the
diffusing capacity does not represent toxicity in every patient (Bell
et al, 1985; Magro et al, 1988); therefore, relying on this test may
lead to unnecessary chemotherapy drug withdrawal. A rapid and
consistent decrease in the diffusing capacity may indicate
impending toxicity and requires careful examination of imaging
data. When radiation therapy is planned after the completion of a
chemotherapeutic schedule, it is advisable to wait for any
chemotherapy-associated decrease in the diffusing capacity to
stabilise or show a trend towards improvement before initiating
radiation therapy. It is difficult to rely on imaging alone to detect
pulmonary toxicity from chemotherapeutic agents, especially in
patients with a background of changes resulting from lung cancer.
Currently, there is no agreement as to how patients on
chemotherapy should be followed using pulmonary function tests
and imaging to reliably and cost-effectively detect therapy-
associated pulmonary complications. Accordingly, attention is
directed towards biological markers of early injury or disease.
Proteomics is a rapidly developing area of biomedical research
that acts as a powerful tool for comprehensive and quantitative
study of dynamic changes in proteins expressed from cells, tissues
or organs under a variety of conditions. It also includes studies of
protein–protein/protein–gene interactions, post-translational
modifications such as phosphorylation or glycosylation, functions
or cellular localisation. There are three components in this
technology: (1) separation of mixtures of proteins/peptides
(multidimensional chromatography); (2) high-sensitivity and
high-throughput mass spectometry; and (3) database searching
and annotation. Two-dimensional electrophoresis has been the
most popular technology used for proteomic analysis, combining
isoelectric protein migration in one dimension and size-deter-
mined separation in the second dimension. This procedure can
resolve hundreds of components on a single gel. While it has
limitations, such as lack of sensitivity for low abundant proteins,
throughput or quantitativeness, there have been revolutionary
improvements in the sensitivity of mass spectrometry, such as
matrix-assisted laser desorption/ionisation time of flight, electro-
spray ionisation tandem mass spectrometry (ESI MS/MS) or
surface-enhanced laser desorption–ionisation. Combination of
microcapillary reverse-phase liquid chromatography with ESI MS/
MS allows for an automated, high-sensitive and quantitative
analysis of peptide mixtures.
The importance of proteomics reflects the major role of proteins
in disease and the fact that proteins constitute a wide range of drug
targets under active research. By studying protein interaction after
drug treatment, proteomics may be used to determine the
pathophysiological basis of disease and further investigate a drug’s
mechanism of action and toxicity. Moreover, proteomics can
identify highly sensitive, specific protein markers and is a
convenient and accurate method for identifying patients suscep-
tible to diseases such as ILD. Furthermore, proteomics may detect
patients presenting in early stages of disease and those most likely
to respond to treatment.
Use of proteomics in clinical interventions
Proteomics studies have been conducted on bronchiolar or nasal
lavage fluid (Lindahl et al, 1999). However, as large amounts of
protein present in sputum play important roles in normal lung
physiology or the pathophysiology of lung disease, it is likely that
proteomics will be increasingly used on sputum samples to
evaluate the roles of different proteins in disease (Vignola et al,
2002). Furthermore, proteomics used for investigating the proteins
involved in tissue repair and destruction may allow for better
characterisation of the extent of airway remodelling in each patient
(Vignola et al, 2002).
The principle of utilising proteomics as a method to obtain
surrogate markers for ILD could use a limited number of patient
enrolments and the creation of a panel of covarying proteins with
disease phenotypes. Hundreds of precandidate proteins can be
reduced to manageable numbers and statistical analysis and
annotation can help elucidate the physiological roles of the
selected proteins in terms of mode of actions of ILD. The selected
protein panel (or protein chip) can then be validated through a
blind test of large-scale patient populations.
Relationship of proteomics to standard biomarkers of
disease
Proteomics can be applied for the mechanistic study of drug
actions by monitoring the phenotypic changes of cell lines and the
corresponding protein expressions in a time-dependent manner.
For example, if 500 serum samples of cancer patients are
investigated, the top 30–50 up- or downregulated proteins of
significance can be selected in correlation with cancer phenotypes,
development stage, metastasis or ILD. Although the majority of
these proteins will be known biomarkers of disease (e.g. SP-D,
LDH, MCP-1), biomarkers involved in apoptosis and the cell cycle
and so on, it is possible to discover novel proteins related to a drug
response or drug resistance.
Hypothetically, almost all diseases are the result of imbalance in
protein expression and by identifying specific profiles using
molecular biology techniques we will have a better understanding
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differential diagnostic antibody chips for lung diseases.
SUMMARY
It is well recognised that many agents, radiotherapy and a range of
diseases, can cause ILD as a complication. Novel EGFR-targeted
agents, such as gefitinib and erlotinib, may contribute an
additional risk to the development of ILD, albeit via a
pharmacological effect through the EGFR rather than directly as
a result of biotransformation or chemical injury. Although a
comprehensive knowledge of the mechanisms involved in the
development of drug-associated ILD has not yet been achieved, the
recent advances in genomics and proteomics may provide an
opportunity to further develop the understanding of this
complicated condition.
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